Headlines about Covidien (NYSE:COV) have been trending somewhat positive recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Covidien earned a news sentiment score of 1.27 on their scale. InfoTrie also gave press coverage about the healthcare company an news buzz score of 10 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have effected Covidien’s analysis:
Covidien has a 1-year low of $65.97 and a 1-year high of $108.57.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/12/08/covidien-cov-given-coverage-optimism-score-of-1-27.html.
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries.
Featured Article: Fiduciary
Receive News & Ratings for Covidien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien and related companies with MarketBeat.com's FREE daily email newsletter.